Alberto Corsini
#149,200
Most Influential Person Now
Researcher
Alberto Corsini's AcademicInfluence.com Rankings
Alberto Corsinicomputer-science Degrees
Computer Science
#7726
World Rank
#8131
Historical Rank
Computational Linguistics
#1601
World Rank
#1618
Historical Rank
Machine Learning
#2956
World Rank
#2993
Historical Rank
Artificial Intelligence
#3249
World Rank
#3297
Historical Rank
Download Badge
Computer Science
Alberto Corsini's Degrees
- PhD Computer Science University of Milan
- Masters Computer Engineering University of Bologna
- Bachelors Computer Engineering University of Bologna
Similar Degrees You Can Earn
Why Is Alberto Corsini Influential?
(Suggest an Edit or Addition)Alberto Corsini's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
- New insights into the pharmacodynamic and pharmacokinetic properties of statins. (1999) (809)
- Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions (2004) (603)
- Risk for myopathy with statin therapy in high-risk patients. (2003) (467)
- Non-lipid-related effects of statins (2000) (292)
- Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease (2005) (276)
- Pharmacology of competitive inhibitors of HMG-CoA reductase. (1995) (263)
- Direct vascular effects of HMG-CoA reductase inhibitors. (1997) (262)
- Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. (1993) (224)
- Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018) (221)
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. (2012) (203)
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors (2011) (183)
- Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. (2010) (170)
- Gender medicine: a task for the third millennium (2013) (165)
- PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. (2005) (164)
- Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. (2013) (157)
- Pleiotropic effects of statins in atherosclerosis and diabetes. (2000) (152)
- Suppressor cells and loss of B-cell potential in mice infected with Trypanosoma brucei. (1977) (141)
- PCSK9 induces a pro-inflammatory response in macrophages (2018) (128)
- Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. (1989) (121)
- Drug‐Induced Liver Injury: The Role of Drug Metabolism and Transport (2013) (117)
- Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. (1997) (111)
- Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties (2013) (108)
- Virtual screening approach for the identification of new Rac1 inhibitors. (2009) (103)
- Low density lipoprotein receptor activity is modulated by soybean globulins in cell culture. (1992) (102)
- Safety considerations for statins (2002) (102)
- Statin drug interactions and related adverse reactions: an update (2018) (101)
- The role of mitochondria in statin‐induced myopathy (2015) (99)
- The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. (2014) (99)
- Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. (1996) (98)
- Statin drug interactions and related adverse reactions (2012) (96)
- Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper (2018) (94)
- Direct effects of statins on the vascular wall. (1998) (93)
- Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. (1993) (90)
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
- Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. (2017) (84)
- Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line* (2015) (82)
- Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. (1992) (81)
- The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk (2003) (81)
- Pharmacokinetics interactions of monoclonal antibodies. (2016) (76)
- Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. (1991) (76)
- Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin (1996) (76)
- Pharmacokinetic drug interactions of the non‐vitamin K antagonist oral anticoagulants (NOACs) (2018) (74)
- Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. (1995) (73)
- PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. (2016) (72)
- Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. (2007) (67)
- Pharmacokinetic interactions between statins and fibrates. (2005) (66)
- PCSK9 inhibition and inflammation: A narrative review. (2019) (64)
- Functional depletion of T- and B-memory cells and other lymphoid cell subpopulations-during trypanosomiasis. (1979) (64)
- A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES. (2019) (62)
- Clinical approach to the inflammatory etiology of cardiovascular diseases (2020) (61)
- Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (2019) (60)
- Drug–drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? (2011) (59)
- Pharmacological interactions of statins. (2002) (59)
- 7S globulin from soybean is metabolized in human cell cultures by a specific uptake and degradation system. (1996) (58)
- Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents (2019) (57)
- Current challenges and controversies in drug-induced liver injury. (2012) (53)
- Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits (2009) (52)
- Effects of calcium antagonists on lipids and atherosclerosis. (1989) (51)
- Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? (2001) (50)
- Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. (2010) (47)
- Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. (2016) (46)
- Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. (2015) (46)
- Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes. (1996) (44)
- Phenotypic Heterogeneity Influences Apoptotic Susceptibility to Retinoic Acid and cis-Platinum of Rat Arterial Smooth Muscle Cells In Vitro: Implications for the Evolution of Experimental Intimal Thickening (2001) (44)
- Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. (1996) (44)
- Simvastatin Reduces MMP1 Expression in Human Smooth Muscle Cells Cultured on Polymerized Collagen by Inhibiting Rac1 Activation (2007) (43)
- Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree (1995) (43)
- Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation (2003) (43)
- Present therapeutic role of cholesteryl ester transfer protein inhibitors (2018) (42)
- Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation (2015) (41)
- Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. (1995) (41)
- Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering (2000) (41)
- PPAR-α agonists are still on the rise: an update on clinical and experimental findings (2017) (39)
- Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. (2011) (39)
- Appropriateness of statin prescription in the elderly. (2018) (39)
- Are pleiotropic effects of statins real? (2007) (38)
- Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. (2016) (38)
- PCSK9: a view beyond the canonical cholesterol lowering impact. (2021) (38)
- Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation (2006) (37)
- Recombinant LCAT (Lecithin: Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome (2019) (36)
- Effect of Valsartan on Angiotensin II–Induced Plasminogen Activator Inhibitor-1 Biosynthesis in Arterial Smooth Muscle Cells (2001) (36)
- Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. (2019) (34)
- Fluvastatin: effects beyond cholesterol lowering. (2000) (34)
- Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals (2018) (34)
- Do structural differences in statins correlate with clinical efficacy? (2010) (33)
- Calcium Antagonists and Low Density Lipoprotein Receptors (1988) (33)
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors and Differences (2011) (33)
- ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials (2019) (32)
- Role of Small GTPase Protein Rac1 in Cardiovascular Diseases: Development of New Selective Pharmacological Inhibitors (2013) (32)
- Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol (2009) (32)
- Effects of lacidipine on experimental models of atherosclerosis (1993) (32)
- Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. (2012) (30)
- Homozygous familial hypobetalipoproteinemia. Increased LDL catabolism in hypobetalipoproteinemia due to a truncated apolipoprotein B species, apo B-87Padova. (1996) (30)
- Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes? (2018) (30)
- (5Z)‐carbacyclin discriminates between prostacyclin‐receptors coupled to adenylate cyclase in vascular smooth muscle and platelets (1987) (29)
- Lipid Lowering Drugs: Present Status and Future Developments (2021) (29)
- Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100. (1992) (28)
- Quantification of In Vitro Cytotoxicity of Surfactants: Correlation with their Eye Irritation Potential (1990) (28)
- Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance (2020) (28)
- Regulation of low density lipoprotein metabolism by 26‐hydroxycholesterol in human fibroblasts (1987) (27)
- Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells (2011) (27)
- Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia. (1986) (27)
- 3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides: a new class of selective Rac inhibitors (2013) (26)
- Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. (2003) (26)
- Drug–drug interaction with statins (2008) (26)
- 2-Amino-3-(phenylsulfanyl)norbornane-2-carboxylate: an appealing scaffold for the design of Rac1-Tiam1 protein-protein interaction inhibitors. (2014) (26)
- Lipoprotein(a): Knowns, unknowns and uncertainties. (2021) (26)
- Fluvastatin: clinical and safety profile. (2004) (25)
- Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes. (1998) (25)
- Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. (2012) (25)
- Incorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins. A useful tool for studying protein prenylation. (1999) (24)
- Calcium antagonists and low density lipoproteins metabolism by human fibroblasts and by human hepatoma cell line HEP G2. (1986) (24)
- Phytosterols, Cholesterol Control, and Cardiovascular Disease (2021) (24)
- Statins effect on smooth muscle cell proliferation. (2004) (24)
- Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism. (2011) (23)
- Lipid-modified proteins as biomarkers for cardiovascular disease: a review (2005) (23)
- Hypolipidemic therapy for the metabolic syndrome. (2006) (23)
- Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. (2008) (23)
- Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. (2011) (23)
- Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. (2009) (22)
- Familial defective apo B‐100, characterization of an Italian family (1991) (22)
- Clinical evidence of statin therapy in non-dyslipidemic disorders. (2014) (22)
- Prognostic parameters of in‐hospital mortality in COVID‐19 patients—An Italian experience (2021) (22)
- Cigarette smoke condensate affects monocyte interaction with endothelium. (2014) (22)
- Recent advances in synthetic pharmacotherapies for dyslipidaemias (2019) (22)
- Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation. (1995) (22)
- Association of physicians’ accuracy in recording with quality of care in cardiovascular medicine (2009) (22)
- Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice (2015) (21)
- Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. (2018) (20)
- Effect of S(-) perillic acid on protein prenylation and arterial smooth muscle cell proliferation. (2001) (20)
- Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications. (2022) (20)
- Fluvastatin treatment is not associated with an increased incidence of cancer (2006) (20)
- Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. (1992) (20)
- High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism. (2019) (20)
- PCSK9 induces a pro-inflammatory response in macrophages (2017) (20)
- Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27Kip1/Cyclin E Expression (2008) (19)
- From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients (2018) (19)
- Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. (2011) (18)
- Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice (2020) (18)
- Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9 (2020) (18)
- Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches (2021) (18)
- Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency. (2007) (18)
- Clinical Pharmacology of Statins: an Update (2020) (18)
- Perivascular carotid collar placement induces neointima formation and outward arterial remodeling in mice independent of apolipoprotein E deficiency or Western-type diet feeding. (2007) (18)
- Monoclonal antibodies to human low density lipoprotein identify distinct areas on apolipoprotein B-100 relevant to the low density lipoprotein-receptor interaction. (1992) (18)
- A simple method of evaluating delayed type hypersensitivity in mice. (1979) (17)
- Statin-Related Muscle Complaints: An Underestimated Risk (2005) (17)
- NAFLD or MAFLD diagnoses and cardiovascular diseases: from epidemiology to drug approaches. (2021) (17)
- ABCA1 and HDL3 are required to modulate smooth muscle cells phenotypic switch after cholesterol loading. (2017) (17)
- Clinical and biochemical characterisation of patients with autosomal recessive hypercholesterolemia (ARH). (2003) (16)
- BINDING-DEFECTIVE LOW-DENSITY LIPOPROTEIN IN FAMILY WITH HYPERCHOLESTEROLAEMIA (1989) (16)
- Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells. (2007) (16)
- Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach (2020) (15)
- The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients (2020) (15)
- Poor response to simvastatin in familial defective apo-B-100 (1991) (15)
- Global Cardiovascular Risk Assessment in Different Clinical Settings (2009) (15)
- Polymorphonuclear leukocyte-myocyte interaction: an early event in collar-induced rabbit carotid intimal thickening. (2002) (15)
- Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion (2013) (14)
- Global cardiovascular risk management in different Italian regions: an analysis of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation (EFFECTUS) educational program. (2012) (14)
- Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. (2018) (14)
- Cholesterol stimulation of HDL binding to human endothelial cells EAhy 926 and skin fibroblasts: evidence for a mechanism independent of cellular metabolism. (1991) (14)
- Plasma lipoproteins and cholesterol metabolism in spontaneously hyperlipemic rats. (1989) (14)
- Susceptibility of inbred mice to Trypanosoma cruzi strain Y. (1980) (14)
- PCSK9 antagonists and inflammation. (2018) (14)
- Use of Electronic Support for Implementing Global Cardiovascular Risk Management (2010) (14)
- In vitro inhibition of arterial myocyte growth and stimulation of low density lipoprotein metabolism by SIM 6080, a new calcium antagonist. (1990) (14)
- Lipoprotein(a) and PCSK9 inhibition: clinical evidence (2020) (14)
- Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. (2019) (14)
- Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds. (2014) (14)
- Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s disease (2019) (13)
- Immunosuppression in mice infected with Trypanosoma cruzi (Chagas, 1909). I--Evidences of polyclonal B cell activation in experimental infections mimicked by an extract prepared from circulating trypomastigotes. (1981) (13)
- Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention (2020) (13)
- Aortic and coronary atheromatosis in a woman with severe hypercholesterolaemia without LDL receptor alterations. (1991) (13)
- Bococizumab for the treatment of hypercholesterolaemia (2017) (13)
- Impact of Diabetes Mellitus on the Clinical Management of Global Cardiovascular Risk: Analysis of the Results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) Educational Program (2011) (13)
- The Antiatherosclerotic Effects of Calcium Antagonists (1995) (12)
- The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? (1998) (12)
- Raloxifene Elicits Combined Rapid Vasorelaxation and Long-Term Anti-Inflammatory Actions in Rat Aorta (2006) (12)
- Geranylgeraniol prevents the simvastatin‐induced PCSK9 expression: Role of the small G protein Rac1 (2017) (12)
- LEPTIN, RESISTIN, AND PCSK9 - THE ROLE OF STAT3. (2020) (12)
- Treatment of dyslipidemia in kidney transplantation (2020) (12)
- New Ras CAAX mimetics: design, synthesis, antiproliferative activity, and RAS prenylation inhibition. (2009) (11)
- Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation. (1993) (11)
- Changes in circulating proprotein convertase subtilisin / kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents (11)
- Potential statin drug interactions in elderly patients: a review (2020) (11)
- Bococizumab for the treatment of hypercholesterolaemia (2017) (11)
- Effects of coffee on plasma lipids, lipoproteins and apolipoproteins. (1989) (11)
- Alternative splicing of mutant LDL-receptor mRNA in an Italian patient with familial hypercholesterolemia due to a partial deletion of LDL-receptor gene (FHPotenza). (1993) (10)
- Lipophilic β-adrenoceptor antagonists stimulate cholesterol biosynthesis in human skin fibroblasts (1987) (10)
- Nitric Oxide-Donating Atorvastatin Attenuates Neutrophil Recruitment During Vascular Inflammation Independent of Changes in Plasma Cholesterol (2013) (10)
- 27‐Hydroxycholesterol modulation of low density lipoprotein metabolism in cultured human hepatic and extrahepatic cells (1993) (10)
- Erratum: New insights into the pharmacodynamic and pharmacokinetic properties of statins (Pharmacology and Therapeutics 84 (3) (413-428)) (2000) (10)
- Proprotein Convertase Subtilisin Kexin Type 9 (2021) (10)
- LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. (2020) (10)
- Suppressor of Cytokine Signaling-3 ( SOCS-3 ) induces Proprotein Convertase Subtilisin Kexin Type 9 ( PCSK 9 ) expression in hepatic HepG 2 cell line * (2015) (10)
- Oxidized LDL‐dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy (2021) (10)
- A fraction (FAd) from Trypanosoma cruzi epimastigotes depresses the immune response in mice. (1980) (10)
- Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis (2019) (10)
- Receptor binding activity of lipid recombinants of apolipoprotein B-100 thrombolytic fragments. (1987) (9)
- ABCA1 and HDL3 are required to modulate smooth muscle cells phenotypic switch after cholesterol loading. (2017) (9)
- The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin (2004) (9)
- Nonprotein sulfhydryls as possible components of the protective effect of rosaprostol on the rat gastric mucosa. (1985) (9)
- Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence. (2020) (8)
- What makes a productive Ph.D. student? (2022) (8)
- Mapping fuel poverty risk at the municipal level. A small-scale analysis of Italian Energy Performance Certificate, census and survey data (2021) (8)
- Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials. (2010) (8)
- An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy (2011) (8)
- Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. (2007) (8)
- Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. (2015) (8)
- Lipophilic beta-adrenoceptor antagonists stimulate low density lipoprotein receptor activity in human skin fibroblasts. (1987) (8)
- Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review (2019) (8)
- Low density lipoprotein (LDL) receptor activity is modulated by soybean globulins in cell culture (1992) (8)
- Progesterone modulates the expression of HDL binding sites in human skin fibroblasts. (1988) (7)
- HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study (2021) (7)
- Calcium, calcium antagonists and experimental atherosclerosis. (1996) (7)
- Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice (2022) (7)
- Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention (2022) (7)
- PGI2 receptors in vasculature and platelets: 5Z-carbacyclin discriminates between them. (1987) (7)
- Vascular smooth muscle and atherosclerosis: Role of isoprenoids and calcium antagonists (1994) (7)
- Experimental studies on the hypolipidemic activity of chloridarol. (1983) (7)
- Current Challenges and Controversies in Drug-Induced Liver Injury (2012) (7)
- Isothiazole dioxide derivative 6n inhibits vascular smooth muscle cell proliferation and protein farnesylation. (2005) (7)
- 6-Keto-prostaglandin E1-sensitive adenylate cyclase and binding sites in membranes from platelets and cultured smooth muscle cells. (1984) (7)
- Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity (2022) (7)
- Statins plus ezetimibe in the era of proprotein convertase subtilisin/kexin type-9 inhibitors. (2020) (6)
- Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells (2021) (6)
- [Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018]. (2018) (6)
- Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2021) (6)
- Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity? (2022) (6)
- Maternal exposure to air pollutants, PCSK9 levels, fetal growth and gestational age - An Italian cohort. (2021) (6)
- Resistance toTrypanosoma cruzi infection in relation to the timing of IgG humoral response (2004) (6)
- In Vitro Angiogenesis Inhibition with Selective Compounds Targeting the Key Glycolytic Enzyme PFKFB3. (2021) (6)
- Simvastatin Reduces MMP 1 Expression in Human Smooth Muscle Cells Cultured on Polymerized Collagen by Inhibiting Rac 1 Activation (2007) (6)
- OMEGA-3 AND CARDIOVASCULAR PREVENTION - IS THIS STILL A CHOICE? (2022) (6)
- Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation (2005) (6)
- Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins (2008) (5)
- Antiatherosclerotic Drugs: A Critical Assessment (1993) (5)
- Trapidil derivatives and low density lipoprotein metabolism by human skin fibroblasts and by human hepatoma cell line Hep G2. (1989) (5)
- Pharmacological Inhibition of Phosholipase A2: Results from Phase 3 Clinical Trials with Darapladib and Varespladib in Patients with Cardiovascular Disease (2015) (5)
- The Role of High-Density Lipoprotein Cholesterol in 2022 (2022) (5)
- Strongyloidiasis and chronic urticaria (1982) (5)
- [Prevention Italy 2021 - An update of the 2018 Consensus document and recommendations for the prevention of cardiovascular disease in Italy]. (2021) (5)
- Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. (2022) (4)
- Differential effects of in vitro ethanol on prostaglandin E1-sensitive adenylate cyclase from smooth muscle cells and platelets. (1985) (4)
- Gender differences in lipoprotein(a) concentration as predictors of coronary revascularization in patients with known coronary artery disease. (2020) (4)
- Lipophilic beta-adrenoceptor antagonists stimulate cholesterol biosynthesis in human skin fibroblasts. (1987) (4)
- Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies (2020) (4)
- Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration (2015) (4)
- Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review (2022) (4)
- Pathogenesis of atherosclerosis and the role of drug intervention (1994) (4)
- Bempedoic Acid: for Whom and When (2022) (4)
- PRECLINICAL STUDIES OF FLUVASTATIN (1996) (4)
- PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin (2021) (4)
- Monoclonal antibody 5A binds apolipoprotein B-48 and inhibits the low density lipoprotein-receptor interaction. (1989) (4)
- Italian familial defective apolipoprotein B patients share a unique haplotype with other Caucasian patients (2001) (4)
- Unimpaired delayed type hypersensitivity reactions in mice infected withTrypanosoma cruzi strain Y (2004) (4)
- Creutzfeldt-Jakob Disease: Correlation of Clinical Neuroradiological Aspects and Detection of 14.3.3. Protein in Cerebrospinal Fluid (2000) (3)
- PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells (2022) (3)
- Lack of correlation between TPA-induced prostaglandin biosynthesis and ornithine decarboxylase activity in Balb/c mouse 3T3 fibroblasts. (1986) (3)
- New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran (2021) (3)
- History and development of HMG-CoA reductase inhibitors (2002) (3)
- Risk Factors for SAMS (2020) (3)
- Pathogenesis of atherosclerosis and the role of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors (1996) (3)
- Statin-associated muscle symptoms: is Proprotein convertase subtilisin/kexin type 9 inhibitors a therapeutic option? (2019) (3)
- Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease (2018) (3)
- Pharmacology of lipoprotein receptors. (1994) (3)
- Th-P16:332 Everolimus affects cholesterol homeostasis in macrophages (2006) (3)
- Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice (2022) (3)
- Immune T cells controlTrypanosoma cruzi infections (2005) (2)
- The dataset describes: Phenotypic changes induced by cholesterol loading in smooth muscle cells isolated from the aortae of C57BL/6 mice (2017) (2)
- Influence of trapidil and derivatives on cholesterol synthesis and esterification in cultured cells. (1991) (2)
- Humoral suppression inTrypanosoma cruzi infection in relation to the timing of antigen presentation (2004) (2)
- Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells (2021) (2)
- LDL-cholesterol control in the primary prevention of cardiovascular diseases: An expert opinion for clinicians and health professionals. (2022) (2)
- Effect of trapidil and its derivatives on the receptor-mediated low density lipoprotein metabolism by cultured human hepatic and extrahepatic cells (1990) (2)
- High density lipoproteins: physiopathology and clinical relevance. (1992) (2)
- Chronic Chagas' disease: unimpaired delayed type hypersensitivity reactions in contrast with humoral suppression to typhoid vaccine. (1981) (2)
- Effect of derivatives of trapidil on the expression of LDL receptors. (1988) (2)
- [Polytherapy and polypharmacy in elderly patients with chronic heart failure]. (2013) (2)
- [The pharmacology of the statins: the evidence of a direct antiatherosclerotic action]. (1995) (2)
- EFFECT OF THE HISTONE DEACETYLASE INHIBITOR TRICHOSTATIN A ON LIPID METABOLISM, TNF-ALPHA PRODUCTION AND SMOOTH MUSCLE CELL PROLIFERATION (2008) (2)
- Impact of physicians’ age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme (2011) (2)
- Pro-inflammatory cytokines and adipokines regulate PCSK9 expression in HepG2 cells (2017) (2)
- PCSK9 modulates phenotype, proliferation and migration of smooth muscle cells in response to PDGF-BB (2017) (2)
- Effect of atherogenic lipoproteins on PAI-1 synthesis by endothelial cells (2004) (2)
- Differential Effects of Red Yeast Rice, Berberis Aristata and Morus Alba Extracts, Active Components of LopiGLIK®, on PCSK9 in HepG2 Cells (2018) (2)
- Lacidipine and Atherosclerosis (1993) (2)
- Tu-P8:299 In vitro enhanced antiproliferative activity of everolimus by fluvastatin on arterial smooth muscle cells (2006) (1)
- 4P-1081 Rosuvastatin displays anti-atherothrombotic properties in apo E-deficient mice (2003) (1)
- Introduction: Principles of therapeutics of fluvastatin (1996) (1)
- Inhibitor-1 Biosynthesis in Arterial Smooth Muscle Cells Effect of Valsartan on Angiotensin II – Induced Plasminogen Activator (2001) (1)
- TNF-alpha induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line in a SOCS-3-dependent manner (2016) (1)
- Proprotein convertase subtilisin/kexin type 9 deficient mice are protected from neointima formation in carotid artery injury model (2014) (1)
- Immunosuppression in mice infected with Trypanosoma cruzi (Chagas, 1909). II--Trypomastigote crude extract (TCE) suppress the humoral immune response in mice. (1981) (1)
- Cerivastatin: A Viewpoint by Alberto Corsini (1998) (1)
- Deficiencies of the LDL-receptor interaction (1989) (1)
- [Bempedoic acid: mechanism of action]. (2021) (1)
- Cigarette smoke aqueous extract: Effects on endothelium, monocytes and their interaction (2017) (1)
- PCSK9 Inhibition and Risk of Diabetes: Should We Worry? (2022) (1)
- SOCS-3 induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line: a potential link between hypertriglyceridemia and insulin resistance (2016) (1)
- Effect of trapidil derivative AR 12456 on intracellular cholesterol homeostasis in human hepatoma cell line Hep G2 (2004) (1)
- Experimental and clinical effects of isradipine relevant to atherosclerosis. (1994) (1)
- Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events: the importance of keeping constant low cholesterol levels. (2017) (1)
- The Antiatherosclerotic Effect of Calcium Antagonists (1995) (1)
- Fibrillar Collagen Inhibits Cholesterol Biosynthesis in Human Aortic Smooth Muscle Cells (2009) (1)
- Lacidipine inhibits arterial myocyte proliferation through a specific modulation of the G1 phase of the cell cycle (1995) (1)
- The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH (2023) (1)
- Review Drug-drug interactions with statins: will pitavastatinovercomethestatins'Achilles'heel? (2011) (1)
- PCSK9 and resistin: Not only a structural sharing (2017) (1)
- [Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells]. (1997) (1)
- Pharmacological control of the mevalonate pathway in the regulation of arterial myocyte proliferation (1995) (0)
- Abstract: P715 EVEROLIMUS INHIBITS MONOCYTE MIGRATION AND THEIR ACCUMULATION IN CAROTID LESIONS OF CHOLESTEROL-FED RABBITS (2009) (0)
- Strongyloidiasis andchronic urticaria (1982) (0)
- 2288Oxidized LDL/CD36/PPARg circuitry is a trigger of adipogenesis in arrhythmogenic cardiomyopathy (2019) (0)
- Effect of atherogenic lipoproteins on PAI-1 synthesis by endothelial cells. (1993) (0)
- Correction to: Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention (2022) (0)
- Role of lipoprotein(a) in plaque progression (2022) (0)
- Role of isoprenoids in normal and pathological cell proliferation (1994) (0)
- New Insights on Simvastatin and Ezetimibe in a Single Tablet (2007) (0)
- Roles of isoprenoids in the control of higher plants cell proliferation (1995) (0)
- Artichoke and bergamot extracts: a new opportunity for the management of dyslipidemia and related risk factors. (2022) (0)
- LIPID LOWERING DRUGS AND THE ARTERIAL WALL (1998) (0)
- Clinico-experimental correlations of triptorelin (TPR) based adjuvant treatment in premenopausal breast cancer patients (PBCP) (2008) (0)
- We-S13:1 Inhibition of cholesterol biosynthesis beyond HMG-CoA reductase: Perspective and advantages (2006) (0)
- Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid (2023) (0)
- 3.P.244 L(−) perillic acid inhibits protein prenylation and the growth of rat and human arterial myocytes “in vitro” (1997) (0)
- Role of Isoprenoids In the Growth-Factor Signal Transduction and their Pharmacological Modulation (1996) (0)
- C24 Inhibitory effect of L(−)perillic acid on protein prenylation and myocyte proliferation (1999) (0)
- Angiotensin-converting enzyme 2 (ACE2): New opportunity or red herring? (2020) (0)
- Contents, Vol. 87, 1996 (1996) (0)
- 1.P.172 Antiatherosclerotic activities of mibefradil in cell culture models (1997) (0)
- The absence of PCSK9 determines a lower neointimal formation in response to perivascular carotid collar placement (2016) (0)
- Established facts, doubts and future perspectives on PGI2 vascular and platelet receptors. (1989) (0)
- SOCS-3 induces PCSK9 expression in hepatic HepG2 cell line (2015) (0)
- 5E and 5Z analogs of prostacyclin in the investigation of PGI2 receptors in platelets and vasculature (1988) (0)
- 118 Ability of simvastatin to inhibit DNA synthesis in PDGF-BB-, EGF-, LPA- and ET-1-stimulated smooth muscle cells (1997) (0)
- P2988Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: role of the small G protein Rac1 (2017) (0)
- Expression and secretion of PCSK9 from cultured smooth muscle cells: evidence for a direct role in atherogenesis (2011) (0)
- PCSK9 deficient mice are protected from neointima formation in carotid artery injury model (2013) (0)
- Extracellular vesicles enriched in PCSK9 are indicative of pro-atherogenic phenotype - in vitro and in vivo evidence (2022) (0)
- In vitro evidence of a pro-inflammatory action of PCSK9 in THP-1-derived macrophages (2016) (0)
- Angiogenesis inhibition with novel compounds targeting the key glycolytic enzyme PFKFB3 (2018) (0)
- The absence of the EDA alternative spliced isoform of fibronectin promotes smooth muscle cells migration and results in neo-intimal hyperplasia (2015) (0)
- Elevated LDL and oxidative stress contribute to arrhythmogenic cardiomyopathy phenotypic manifestation (2016) (0)
- Pharmacological modulation of lipid metabolism in a human cell line alters protein content and signalling of secreted extracellular vesicles (2022) (0)
- Familial recessive hypercholesterolemia (FRH): Characterization of 10 homozygotes and 9 obligate heterozygotes (2000) (0)
- Erratum: Heber et al., “Mice with Combined Gene Knock-Outs Reveal Essential and Partially Redundant Functions of Amyloid Precursor Protein Family Members” (2020) (0)
- Efect of calcium antagonist SIM6080 on myocyte proliferation: Comparison with calcium channel blockers and calmodulin antagonists (1990) (0)
- PO9-218 IN VITRO AND IN VIVO STUDIES OF ANTIATHEROSCLEROTIC PROPERTIES OF EVEROLIMUS (2007) (0)
- Glycolysis Inhibition Suppresses Angiogenesis (2019) (0)
- ABCA1 and HDL3 are required to modulate smooth muscle cells phenotypic switch induced by cigarette smoke (2018) (0)
- (5Z)-carbacyclin displays agonist-antagonist properties on prostacyclin-receptors in platelets and vascular myocytes. (1988) (0)
- Abstract 435: Inhibition of the Key Glycolytic Enzyme PFKFB3 with Novel Compounds Suppresses Angiogenesis (2018) (0)
- STAT3 inhibition induces PCSK9 in hepatic cell line: possible involvement in hypertriglyceridemia associated with insulin resistance (2015) (0)
- Clinical tolerability and safety profile of CER-001, a novel bio-engineered pre-β HDL-mimetic, across the clinical development programme (2016) (0)
- Inhibition of smooth muscle cell proliferation by sera of fluvastin treated subjects with type IIa hypercholesterolemia (1995) (0)
- Similarities and Differences between Angiotensin II Type 1 Receptor Antagonists (2004) (0)
- Use of biotechnology and drugs for an integrative approach to pathophysiology (1994) (0)
- Studies on the mechanism of action of the antiproliferative effect of no-donors furoxans in smooth muscle cells (2016) (0)
- Abstract: P712 SMOOTH MUSCLE CELLS TRANSDIFFERENTIATION TO MACROPHAGE-LIKE CELLS (2009) (0)
- THE VASORELAXANT AND ANTI-INFLAMMATORY ACTION OF RALOXIFENE IN RAT AORTA IS PARTIALLY MEDIATED BY ESTROGEN RECEPTOR ALPHA (2007) (0)
- PCSK9 expression is regulated by pro-inflammatory cytokines and adipokines in HEPG2 cells (2016) (0)
- Adipose tissue related adipokines and cytokines regulate PCSK9 expression in HepG2 cells (2016) (0)
- Effect of propranolol on cholesterol metabolism in human skin fibroblasts (1988) (0)
- Farnesyltransferanse and geranylgeranyltransferase inhibitors (1995) (0)
- Control of human artery cell proliferation by inhibitors of HMGCoA reductase (1992) (0)
- STATIN-ASSOCIATED MUSCLE SYMPTOMS: IS PCSK9 INHIBITORS A THERAPEUTIC OPTION? (2018) (0)
- 48 ABCA 1 MODULATES CELLULAR MIGRATION AND MEMBRANE RUFFLING INDUCED BY FREE CHOLESTEROL IN MACROPHAGE FOAM CELLS (2008) (0)
- Inhibition of the Key Glycolytic Enzyme PFKFB3 with Novel Compounds Suppresses Vessel Sprouting (2018) (0)
- TERM ANTI-INFLAMMATORY ACTIONS IN RAT AORTA (2006) (0)
- Smooth muscle cells PCSK9 knock-out exhibit an impaired response to PDGF stimulation (2016) (0)
- Inhibition of low density lipoprotein receptor-mediated endocytosis in human fibroblasts by calcium ionophores (1988) (0)
- May cellular lipids and oxidative stress play a role in arrhythmogenic cardiomyopathy pathogenesis? A lipidomic study in cardiac mesenchymal stromal cells (2018) (0)
- 1 Differential effects of red yeast rice , Berberis aristata 2 and Morus alba extracts , active components of 3 LopiGLIK ® , on PCSK 9 in HepG 2 cells 4 (2018) (0)
- Proteomic studies to assess the mechanism of action of the antiproliferative effect of furoxans in smooth muscle cells (2017) (0)
- Effect of simvastatin in subjects with familial defective apolipoprotein B-100 (1990) (0)
- 3.P.257 Picotamide, an antithromboxane agent, prevents the migration and growth of rat and human arterial myocytes “in vitro” (1997) (0)
- Effects on Plasma Cholesterol versus Local Effects on the Arterial Wall Exerted by 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (1993) (0)
- 17 The pharmacological control of the mevalonate pathway regulates arterial smooth muscle cell proliferation (1997) (0)
- In Vitro Characterization of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Breast Cancer Cells (2021) (0)
- Rosuvastatin reduces inflammation and atherothrombosis in apoE‐deficient mice (2005) (0)
- Development of new Rac1 inhibitors as potential pharmacological agents for the treatment of atherosclerosis (2013) (0)
- Causes Underlying the Reduced Response to Simvastatin Treatment in Hypercholesterolemic Patients (1993) (0)
- Pollution from fine particulate matter and atherosclerosis: A narrative review. (2023) (0)
- Monoclonal antibodies in detecting areas of apolipoprotein B-100 involved in the LDL-receptor interaction (1990) (0)
- Abstract: P716 ABCA1 MODULATE CELLULAR MIGRATION AND MEMBRANE RUFFLING INDUCED BY FREE CHOLESTEROL IN MACROPHAGES FOAM CELLS (2009) (0)
- Direct drug control of the vascular walls (1994) (0)
- Tu-P7:76 Effect of genotype and diet on carotid lesions induced by perivascular collar placement in ApoE-/- and wild-type mice (2006) (0)
- Welcome to European Atherosclerosis Journal, a new Open Access Journal: European Atherosclerosis Journal, a new Open Access Journal (2022) (0)
- Abstract 035: Recombinant LCAT Restores Defective HDL mediated Endothelial Protection in Acute Coronary Syndrome (2018) (0)
- HMG-CoA reductase inhibitors (Vastatins) on isoprenylation and cell multiplication (1995) (0)
- Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on migration, proliferation and cholesterol homeostasis in arterial myocytes (1995) (0)
- Isothiazoles. Part 15. A Mild and Efficient Synthesis of New Antiproliferative 5-Sulfanylsubstituted 3-Alkylaminoisothiazole 1,1-Dioxides. (2006) (0)
- Effects of saponaceolide A and derivatives on proliferation of arterial myocytes: Structure-activity relationships (1995) (0)
- Effects of uvidin A and derivatives on proliferation of arterial myocytes: Structure-activity relationships (1995) (0)
- [Uncertainties in cardiovascular risk factors: sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity?] (2023) (0)
- Smooth Muscle Cell Phenotypic Switch Induced by Traditional Cigarette Smoke Condensate: A Holistic Overview (2023) (0)
- Novel MMP-inhibiting peptides for stabilizing atherosclerotic plaques. (2017) (0)
- The efficacy of mineral corticoid receptor antagonist, canrenone, in COVID-19 patients (2020) (0)
- Characterization of Monoclonal Antibodies to Human Low Density Lipoprotein (1989) (0)
- LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters (2020) (0)
- Subject Index Vol. 87,1996 (1996) (0)
- HMGCoA Reductase Enzyme Inhibitors Effects on Proliferation of Arterial Myocytes (1993) (0)
- Fluid–Structure Computational Analysis to Investigate the Link between Early Atherogenic Events and the Hemodynamic Environment in an Experimental Model of Intimal Thickening (2012) (0)
- Leptin and resistin affect PCSK9 expression via STAT3 involvement. (2017) (0)
- Neurobiology of Disease Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington ’ s Disease (0)
- P153role of fibronectin extra domain-a (fn-eda) in neo-intima formation and arterial remodelling in mouse models (2012) (0)
- Effect of trapidil derivative AR 12456 on intracellular cholesterol homeostasis in human hepatoma cell line Hep G2. (1993) (0)
- VirtualScreeningApproachfortheIdentification of New Rac1 Inhibitors (2009) (0)
- Abnormalities of Apolipoprotein B Metabolism in the Lipid Clinic (1991) (0)
- 455 THE CLASS II PHOSPHOINOSITIDE 3-KINASE ISOFORM β REGULATES PLATELET FUNCTION AND ARTERIAL THROMBOSIS IN MICE (2011) (0)
- Regulatory relevance of lipoproteins in interleukin-2 stimulated lymphocytes in vitro. (1993) (0)
- Separation and characterization of different populations of extracellular vesicles secreted by a human lymph-node metastatic cell line (2020) (0)
- Abstract 605: Inhibition of the Key Glycolytic Enzyme PFKFB3 with Novel Compounds Suppresses Angiogenesis (2018) (0)
- Male patients with hypogonadism have an impaired lipoprotein function (2019) (0)
- In vitro studies on the mechanisms exerted by a mixture of lactobacillus plantarum alone or combined with berberine and fermented red rice on cholesterol homeostasis (2022) (0)
- DSEA, University of Padova and OIPE (2020) (0)
- Erratum: Valenza et al., “Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease” (2020) (0)
- Materials and methods ENDOTHELIAL CELL CULTURES Human umbilical vein (2004) (0)
- Abstract 138: Cigarette Smoke and Monocytes Induce Endothelial Dysfunction (2015) (0)
- Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril. (2022) (0)
- [Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk]. (2014) (0)
- ABCA1 and HDL3 are Required to Modulate Smooth Muscle Cells Transdifferentiation in a Myocardin-miR143/145-Dependent Process (2016) (0)
- 765 NITRIC OXIDE-DONATING STATINS EXERT BENEFICIAL EFFECTS ON ACUTE VASCULAR INFLAMMATION IN NORMOCHOLESTEROLEMIC RABBITS (2011) (0)
- Safety of Dyslipidemic Agents (2016) (0)
- P356 CHOLESTEROL LOADING INDUCES SMOOTH MUSCLE CELLS TRANSDIFFERENTIATION TO MACROPHAGE-LIKE CELLS (2010) (0)
- C25 Pharmacological control of myocyte proliferation by different farnesyltransferase inhibitors (1999) (0)
- Drug–Drug Interaction with DOACs (2021) (0)
- [Familial hypercholesterolemia. Study of low-density lipoprotein receptors. Treatment with plasmapheresis]. (1986) (0)
- Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity? (2022) (0)
- Characterization of a family with moderate hypercholesterolemia and binding defective low density lipoprotein (1992) (0)
- E verolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits (2008) (0)
- PCSK9, SINDROME METABOLICA E DIABETE (2017) (0)
- Drugs Protecting the Arterial Wall (1996) (0)
- Plasma PCSK9 levels and lipoprotein distribution are preserved in patients with severe hypoalphalipoproteinemia. (2017) (0)
- PCSK9 e aterosclerosi: solo LDL colesterolo? = PCSK9 and atherosclerosis: effects beyond LDL cholesterol (2017) (0)
- Positive modulation of mGlu5 reverses ASD-like behaviors found in SHANK3 knock-out mice (2016) (0)
- Leaf extract of morus alba reduces the expression of proprotein convertase subtilisin kexin type 9 (PCSK9) in HEPG2 cell line (2018) (0)
- Fluid–Structure Computational Analysis to Investigate the Link between Early Atherogenic Events and the Hemodynamic Environment in an Experimental Model of Intimal Thickening (2012) (0)
- Direct drug control of the vascular wall. (1995) (0)
- Antiproliferative effect of furoxans in smooth muscle cells: Proteomic studies to unravel their mechanism of action. (2017) (0)
- A quantitative method for determining Toxoplasma gondii, white cells, and the volume of ascitic fluid in experimentally infected mice. (1980) (0)
- Vascular myocytes preserve phenotypic features in culture (2005) (0)
- 3.P.239 Pharmacological control of protein prenylation and arterial smooth muscle cell proliferation (1997) (0)
- P320Contribution of oxidized low density lipoproteins to arrhythmogenic cardiomyopathy adipogenesis (2018) (0)
- Novel compounds targeting PFKFB3, the key glycolytic enzyme, as a way to inhibit angiogenesis (2017) (0)
- Journal Pre-proof LDL-cholesterol control in the primary prevention of cardiovascular diseases: An Expert Opinion for clinicians and health professionals (2022) (0)
- LE-4. Pharmacological control of atherosclerotic plaques (1997) (0)
- In vitro inhibition of rat arterial smooth muscle cell growth by extractive sulfated mucopolysaccharides. (1985) (0)
- Results of the Heart Protection Study: can we still assume a class effect? (2003) (0)
- Role of mevalonate in smooth muscle cell proliferation (1995) (0)
- [Pharmacological characteristics of new oral anticoagulants]. (2015) (0)
- Leptin and resistin affect PCSK9 expression: In vitro and in vivo evidence (2018) (0)
- Size, fatty acid and protein characterization of different populations of extracellular vesicles obtained by sequential centrifugation. An useful tool to dissect their biological properties? (2022) (0)
- Further studies with 5E and 5Z analogues of PGI2 in platelets and vasculature. (1989) (0)
- Ability of simvastatin to inhibit DNA synthesis of platelet-derived growth factor- and epidermal growth factor-stimulated smooth muscle cells (1995) (0)
- Effects of traditional cigarette and electronic cigarette on smooth muscle cell phenotypic modulation (2022) (0)
- Tu-P8:300 Sera from patients treated with fluvastatin XL inhibit human arterial myocyte proliferation (2006) (0)
- VascularSMCproliferationisacrucialeventinocclusivecardiovasculardiseases.PPARαisanuclearrecep- torcontrollinglipidmetabolismandinflammation,butitsroleintheregulationofSMCgrowthremains tobeestablished.Here,weshowthatPPARα controlsSMCcell-cycleprogressionattheG 1 /Stransitionby (2005) (0)
- Atherogenic lipoproteins regulate PAI-1 release by endothelial cells (1991) (0)
- Overexpression of PCSK9 in human smooth muscle cells renders extracellular vesicles atherogenic. (2021) (0)
- Non-lipid-related effects of HMG-CoA reductase inhibitors (1995) (0)
- IL08 Prenylation of protein: Roles and pharmacological regulation (1996) (0)
- Cigarette smoke and monocytes : a dangerous relationship for the endothelium? (2014) (0)
- Cigarette smoke aqueous extract affects endothelium, monocytes and their interaction. (2017) (0)
- Effect of Statins Beyond Lowering Cholesterol: Where Do We Stand? (1998) (0)
- Selected Drugs That May Increase Risk of Myopathy and Rhabdomyolysis When Used Concomitantly With Statins CYP (2004) (0)
- Influence of PCSK9 on biological behavior of mouse smooth muscle cells. (2017) (0)
- 3.P.247 Farnesol and geranylgeraniol prevent the inhibition elicited by simvastatin on proliferation and actin polymerization in rat arterial smooth muscle cells (1997) (0)
- MOGLYNET – Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study – H2020 (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alberto Corsini?
Alberto Corsini is affiliated with the following schools:
